Archon Biosciences' antibody cages (AbCs) enhance therapeutic efficacy by increasing the binding probability of antibodies to target proteins, thus enabling more effective drug development.
David Baker's pioneering work in generative protein design has laid a foundation for Archon Biosciences, which aims to transform antibody treatments by designing scaffold proteins that maximize therapeutic effects.
Collection
[
|
...
]